greffe fécale nouvelle

For the first time in Canada, a team from the CHUM Research Centre (CRCHUM) will study the efficacy of a therapy combining intestinal microbiota and immunotherapy to treat melanoma.

Dr. André Robidoux

At the CRCHUM Conference on March 12th, we will honour André Robidoux, M.D., who passed away on July  25, 2020, from an incurable cancer.

PROTECT study

As part of a large research project to evaluate the protective effect of vitamin D against COVID-19, CHU Sainte-Justine (CHUSJ) and the Centre hospitalier de l’Université de Montréal (CHUM) are seeking healthcare staff who have direct contact with patients or colleagues and who wish to participate in this important work.

Application

Eighty-five per cent of staffers in hospitals and long-term-care centres coped well with the mental stress they experienced during and after the first wave of the COVID-19 pandemic last year.

Anne-Marie Mes-Masson, a researcher with the CHUM Research Centre’s Cancer Research Theme, has received the 2020 Acfas Léo-Pariseau Award.

Anne-Marie Mes-Masson

A regular researcher with the CHUM Research Centre’s Cancer Research Theme, Anne-Marie Mes-Masson joined the ranks of Canada’s Most Powerful Women: Top 100 this year, in the Science and Technology category.

Fred Saad

The medical field of prostate cancer has produced a wealth of doctors and researchers whose work has led to major scientific advances in treatment of the disease.

Cynthia Ménard

In an interview conducted remotely due to the pandemic, Dr. Cynthia Ménard, on the other side of the screen, exudes an air of serenity that seems to be a permanent fixture of her personality.

Journée scientifique

Not getting enough fresh air lately? Boost your brain’s oxygen supply in the company of Sir Peter J. Ratcliffe, the 2019 Nobel Prize laureate in physiology or medicine. On November 12th, the British researcher will explain how our cells adapt to a lack of oxygen, allowing us to live. 

A team from the CHUM Research Centre (CRCHUM) and Polytechnique Montréal combines Raman microspectroscopic imaging with machine learning techniques to better detect aggressive forms of prostate cancer, making diagnosis accurate almost 9 times out of 10.